
Keywords: SA-βgal; senescence-associated β-galactosidase; SASP; senescence-associated secretory phenotype; FDA; Food and Drug Administration; GHRKO; growth hormone receptor knockout; ATTAC; apoptosis through targeted activation of caspase 8; BubR1; budding uninhi